The Anti-TNF Alpha Therapy Against Congestive Heart Failure (ATTACH) trial demonstrated higher rates of HF-related hospitalization or death in the patients with New York Heart Association class III or IV HF receiving infliximab, a TNF alpha inhibitor [24]. The gene discussed is TNF; the disease is congestive heart failure.